Preventive Action Limit legislation

Some practices utilized by brand firms to delay generic competition have been the target of recent FTC and legislative actions. One concern was the practice of listing several new patents late in the product life cycle in an apparent effort to trigger successive 30-month stays to delay generic competition. To prevent this practice, the Medicare Prescription Drug, Improvement, and Modernization Act of 2003 limited each branded product to one 30-month stay (Padden and lenkins 2004). 

---